Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more
Aktis Oncology, Inc. Common stock (AKTS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.146x
Based on the latest financial reports, Aktis Oncology, Inc. Common stock (AKTS) has a cash flow conversion efficiency ratio of 0.146x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.80 Million) by net assets ($-87.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aktis Oncology, Inc. Common stock - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Aktis Oncology, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aktis Oncology, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aktis Oncology, Inc. Common stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ambitions Enterprise Management Co. L.L.C Class A Ordinary Shares
NASDAQ:AHMA
|
0.032x |
|
BLUELAKE MINERAL AB
F:5KG0
|
N/A |
|
Vertiqal Studios Corp.
PINK:VERTF
|
0.213x |
|
Heng Sheng Holding Group Limited
KQ:900270
|
0.011x |
|
CL Educate Limited
NSE:CLEDUCATE
|
0.060x |
|
CATENON SA INH. EO-02
F:8Y9
|
N/A |
|
Prashkovsky
TA:PRSK
|
-0.029x |
|
SIMPPLE LTD. Ordinary Shares
NASDAQ:SPPL
|
-0.640x |
Annual Cash Flow Conversion Efficiency for Aktis Oncology, Inc. Common stock (2014–2024)
The table below shows the annual cash flow conversion efficiency of Aktis Oncology, Inc. Common stock from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-87.80 Million | $14.76 Million | -0.168x | -123.79% |
| 2024-06-30 | $-57.09 Million | $-40.35 Million | 0.707x | +9.06% |
| 2023-12-31 | $-46.31 Million | $-30.00 Million | 0.648x | +224.67% |
| 2023-06-30 | $86.24 Million | $-44.82 Million | -0.520x | -155.14% |
| 2022-12-31 | $-19.23 Million | $-18.12 Million | 0.943x | +315.70% |
| 2022-06-30 | $103.43 Million | $-45.20 Million | -0.437x | 0.00% |
| 2021-12-31 | $103.43 Million | $-45.20 Million | -0.437x | -74.72% |
| 2021-06-30 | $117.41 Million | $-29.36 Million | -0.250x | +51.29% |
| 2020-12-31 | $41.49 Million | $-21.30 Million | -0.513x | 0.00% |
| 2020-06-30 | $41.49 Million | $-21.30 Million | -0.513x | +24.57% |
| 2019-12-31 | $25.95 Million | $-17.67 Million | -0.681x | 0.00% |
| 2019-06-30 | $25.95 Million | $-17.67 Million | -0.681x | +33.61% |
| 2018-12-31 | $13.85 Million | $-14.20 Million | -1.025x | 0.00% |
| 2018-06-30 | $13.85 Million | $-14.20 Million | -1.025x | -177.37% |
| 2017-12-31 | $15.01 Million | $-5.55 Million | -0.370x | 0.00% |
| 2017-06-30 | $15.01 Million | $-5.55 Million | -0.370x | +10.09% |
| 2016-06-30 | $2.68 Million | $-1.10 Million | -0.411x | 0.00% |
| 2015-12-31 | $2.68 Million | $-1.10 Million | -0.411x | -75.57% |
| 2015-06-30 | $4.19 Million | $-980.04K | -0.234x | 0.00% |
| 2014-12-31 | $4.19 Million | $-980.04K | -0.234x | +92.00% |
| 2014-06-30 | $9.21K | $-26.98K | -2.928x | -- |